HSP27, ALDH6A1 and prohibitin act as a trio-biomarker to predict survival in late metastatic prostate cancer

Sung Yong Cho, Suki Kang, Dong Su Kim, Hyung Jin Na, Ye Jin Kim, Young Deuk Choi, Nam Hoon Cho

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aim: The aim of this study was to evaluate the usefulness of biomarkers related to prostate cancer metastasis and survival of patients. Materials and Methods: Proteomics were used for detecting significant differences in protein expression among normal prostate, localized prostate cancer and metastatic cancer using 2-dimensional gel electrophoresis and mass spectrometry. mRNA expression was then examined in order to further confirm significant differences in protein expression. A total of 7 proteins were found to be differentially expressed. Immunochemistry (IHC), was also used to confirm the levels of expression of the 7 proteins in prostate cancer. Survival analysis using the candidate markers was finally performed in 98 metastatic prostate cancer patients according to IHC results. Results: In metastatic lesions, proteomic analysis indicated that heat shock protein (HSP) 27, prohibitin, glutathione S-transferase 1, fibrinogen β chain, and aldehyde dehydrogenase 6A1 were up-regulated, while α1 antitrypsin, and HSP 60 were down-regulated. IHC revealed that HSP 27, ALDH6A1 and prohibitin were highly specific to metastatic tumor cells. HSP27 and prohibitin appeared more strongly in the incipient stage of cancer than metastatic cancer, and ALDH6A1 was significantly reduced in metastatic cancer (p<0.01). Of all proteins, phohibitin had the highest value in predicting survival. However, all three proteins were a stronger marker than each one separately. Conclusion: Trio-biomarker composed of HSP27, ALDH6A1 and prohibitin may predict survival of metastatic prostate cancer patients.

Original languageEnglish
Pages (from-to)6551-6560
Number of pages10
JournalAnticancer research
Volume38
Issue number11
DOIs
Publication statusPublished - 2018 Nov

Fingerprint

Prostatic Neoplasms
Biomarkers
Survival
HSP27 Heat-Shock Proteins
Proteins
Neoplasms
Proteomics
Chaperonin 60
Immunochemistry
Aldehyde Dehydrogenase
Survival Analysis
Glutathione Transferase
Fibrinogen
Electrophoresis
prohibitin
Prostate
Mass Spectrometry
Gels
Neoplasm Metastasis
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Cho, Sung Yong ; Kang, Suki ; Kim, Dong Su ; Na, Hyung Jin ; Kim, Ye Jin ; Choi, Young Deuk ; Cho, Nam Hoon. / HSP27, ALDH6A1 and prohibitin act as a trio-biomarker to predict survival in late metastatic prostate cancer. In: Anticancer research. 2018 ; Vol. 38, No. 11. pp. 6551-6560.
@article{7d8cef9fa7604f59ab952086f2bbe8bf,
title = "HSP27, ALDH6A1 and prohibitin act as a trio-biomarker to predict survival in late metastatic prostate cancer",
abstract = "Background/Aim: The aim of this study was to evaluate the usefulness of biomarkers related to prostate cancer metastasis and survival of patients. Materials and Methods: Proteomics were used for detecting significant differences in protein expression among normal prostate, localized prostate cancer and metastatic cancer using 2-dimensional gel electrophoresis and mass spectrometry. mRNA expression was then examined in order to further confirm significant differences in protein expression. A total of 7 proteins were found to be differentially expressed. Immunochemistry (IHC), was also used to confirm the levels of expression of the 7 proteins in prostate cancer. Survival analysis using the candidate markers was finally performed in 98 metastatic prostate cancer patients according to IHC results. Results: In metastatic lesions, proteomic analysis indicated that heat shock protein (HSP) 27, prohibitin, glutathione S-transferase 1, fibrinogen β chain, and aldehyde dehydrogenase 6A1 were up-regulated, while α1 antitrypsin, and HSP 60 were down-regulated. IHC revealed that HSP 27, ALDH6A1 and prohibitin were highly specific to metastatic tumor cells. HSP27 and prohibitin appeared more strongly in the incipient stage of cancer than metastatic cancer, and ALDH6A1 was significantly reduced in metastatic cancer (p<0.01). Of all proteins, phohibitin had the highest value in predicting survival. However, all three proteins were a stronger marker than each one separately. Conclusion: Trio-biomarker composed of HSP27, ALDH6A1 and prohibitin may predict survival of metastatic prostate cancer patients.",
author = "Cho, {Sung Yong} and Suki Kang and Kim, {Dong Su} and Na, {Hyung Jin} and Kim, {Ye Jin} and Choi, {Young Deuk} and Cho, {Nam Hoon}",
year = "2018",
month = "11",
doi = "10.21873/anticanres.13021",
language = "English",
volume = "38",
pages = "6551--6560",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

HSP27, ALDH6A1 and prohibitin act as a trio-biomarker to predict survival in late metastatic prostate cancer. / Cho, Sung Yong; Kang, Suki; Kim, Dong Su; Na, Hyung Jin; Kim, Ye Jin; Choi, Young Deuk; Cho, Nam Hoon.

In: Anticancer research, Vol. 38, No. 11, 11.2018, p. 6551-6560.

Research output: Contribution to journalArticle

TY - JOUR

T1 - HSP27, ALDH6A1 and prohibitin act as a trio-biomarker to predict survival in late metastatic prostate cancer

AU - Cho, Sung Yong

AU - Kang, Suki

AU - Kim, Dong Su

AU - Na, Hyung Jin

AU - Kim, Ye Jin

AU - Choi, Young Deuk

AU - Cho, Nam Hoon

PY - 2018/11

Y1 - 2018/11

N2 - Background/Aim: The aim of this study was to evaluate the usefulness of biomarkers related to prostate cancer metastasis and survival of patients. Materials and Methods: Proteomics were used for detecting significant differences in protein expression among normal prostate, localized prostate cancer and metastatic cancer using 2-dimensional gel electrophoresis and mass spectrometry. mRNA expression was then examined in order to further confirm significant differences in protein expression. A total of 7 proteins were found to be differentially expressed. Immunochemistry (IHC), was also used to confirm the levels of expression of the 7 proteins in prostate cancer. Survival analysis using the candidate markers was finally performed in 98 metastatic prostate cancer patients according to IHC results. Results: In metastatic lesions, proteomic analysis indicated that heat shock protein (HSP) 27, prohibitin, glutathione S-transferase 1, fibrinogen β chain, and aldehyde dehydrogenase 6A1 were up-regulated, while α1 antitrypsin, and HSP 60 were down-regulated. IHC revealed that HSP 27, ALDH6A1 and prohibitin were highly specific to metastatic tumor cells. HSP27 and prohibitin appeared more strongly in the incipient stage of cancer than metastatic cancer, and ALDH6A1 was significantly reduced in metastatic cancer (p<0.01). Of all proteins, phohibitin had the highest value in predicting survival. However, all three proteins were a stronger marker than each one separately. Conclusion: Trio-biomarker composed of HSP27, ALDH6A1 and prohibitin may predict survival of metastatic prostate cancer patients.

AB - Background/Aim: The aim of this study was to evaluate the usefulness of biomarkers related to prostate cancer metastasis and survival of patients. Materials and Methods: Proteomics were used for detecting significant differences in protein expression among normal prostate, localized prostate cancer and metastatic cancer using 2-dimensional gel electrophoresis and mass spectrometry. mRNA expression was then examined in order to further confirm significant differences in protein expression. A total of 7 proteins were found to be differentially expressed. Immunochemistry (IHC), was also used to confirm the levels of expression of the 7 proteins in prostate cancer. Survival analysis using the candidate markers was finally performed in 98 metastatic prostate cancer patients according to IHC results. Results: In metastatic lesions, proteomic analysis indicated that heat shock protein (HSP) 27, prohibitin, glutathione S-transferase 1, fibrinogen β chain, and aldehyde dehydrogenase 6A1 were up-regulated, while α1 antitrypsin, and HSP 60 were down-regulated. IHC revealed that HSP 27, ALDH6A1 and prohibitin were highly specific to metastatic tumor cells. HSP27 and prohibitin appeared more strongly in the incipient stage of cancer than metastatic cancer, and ALDH6A1 was significantly reduced in metastatic cancer (p<0.01). Of all proteins, phohibitin had the highest value in predicting survival. However, all three proteins were a stronger marker than each one separately. Conclusion: Trio-biomarker composed of HSP27, ALDH6A1 and prohibitin may predict survival of metastatic prostate cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85056124512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056124512&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13021

DO - 10.21873/anticanres.13021

M3 - Article

C2 - 30396985

AN - SCOPUS:85056124512

VL - 38

SP - 6551

EP - 6560

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -